Pfizer will begin providing the treatments to the US government later this year through the end of 2022.
Washington:
Pfizer said on Thursday it will sell 10 million COVID-19 treatments for COVID-19 to the US government for $5.3 billion, pending approval from regulators.
The drug giant asked the US Food and Drug Administration on Tuesday for an emergency use authorization for its Paxlovid antiviral pill that has been shown to help reduce hospital admissions. or nearly 90% mortality in high-risk newly infected patients treated within three days of symptom onset.
“We are delighted with the recent results of our Phase 2/3 interim analysis, which shows the remarkable effectiveness of PAXLOVID … and are delighted that the US government recognizes this potential.” , Pfizer President and CEO Albert Bourla said in a statement.
“It is encouraging to see the growing understanding of the valuable role that investigative oral therapies can play in combating COVID-19 and we look forward to continuing our discussions with governments. around the world to help ensure universal access for people everywhere.”
Pfizer will begin providing the treatments to the US government later this year through the end of 2022, the statement said.
The company has also entered into pre-purchase agreements with a number of other countries and initiated bilateral outreach to about 100 countries around the world, while committing to a “fair access” to treatment. with affordable prices.
On Tuesday, it announced an agreement with the UN-backed Medicines Patent Organization (MPP) to license sub-manufacturing to supply 95 low- and middle-income countries, representing about 53% of the total. World Population.
The move comes a few weeks after Merck also reached out to the FDA to seek a green light for its antiviral capsule against the coronavirus.
(Except for the title, this story has not been edited by NDTV staff and is published from an aggregated feed.)
